Results 141 to 150 of about 80,546 (217)

Early Phase Dose‐Finding Designs for CAR‐T Cell Therapies

open access: yesPharmaceutical Statistics, Volume 25, Issue 4, July/August 2026.
ABSTRACT Chimeric Antigen Receptor (CAR)‐T cell is an immunotherapy which revolutionised the treatment of relapsed/refractory lymphoma and leukaemia. It is shown to have a higher response rate, higher mid‐to‐long term overall survival, and lower toxicity than standard treatments.
Weishi Chen   +3 more
wiley   +1 more source

Exploiting Device Deformability for Fluid and Particle Manipulation

open access: yesSmall, Volume 22, Issue 39, 13 July 2026.
Deformable devices enable fluid and particle manipulation modes that are inaccessible to rigid platforms. This review examines soft materials and architectures that translate controlled deformation into microscale fluid operations such as pumping, valving, mixing, and particle handling.
Zhiyang Hong   +4 more
wiley   +1 more source

Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease

open access: yes
HemaSphere, Volume 10, Issue 7, July 2026.
Mirjeta Berisha   +16 more
wiley   +1 more source

Stimuli‐Responsive Aggregation‐Induced Emission Materials for Tumor Theranostics: Design Strategies and Biomedical Applications

open access: yesSmall Science, Volume 6, Issue 7, July 2026.
pH, enzyme, hypoxia/redox, temperature, and external trigger‐responsive AIE materials for tumor imaging and therapy. Smart‐responsive aggregation‐induced emission (AIE) materials have emerged as promising bio‐nanomaterials for tumor diagnosis and therapy due to their enhanced fluorescence in aggregated states, overcoming the aggregation‐caused ...
Zhaohua Xu   +8 more
wiley   +1 more source

Risk of SARS‐CoV‐2 Infection and Hospitalisation in Immunocompromised Children: A Population‐Based Cohort Study in Italy and Norway

open access: yesActa Paediatrica, Volume 115, Issue 7, Page 1451-1460, July 2026.
ABSTRACT Aim Immunocompromised children (IC) were presumed to be at higher risk of SARS‐COV‐2 infection and severe COVID‐19, but population‐based evidence is limited. We assessed infection risk, COVID‐19 hospitalisation, and severe outcomes in IC compared with children with and without other high‐risk conditions.
Costanza Di Chiara   +13 more
wiley   +1 more source

Antigen-specific B cell responses in treatment-naive and chlorambucil-treated patients with chronic lymphocytic leukemia. [PDF]

open access: yesSci Rep
Šlisere B   +7 more
europepmc   +1 more source

Incorporation of Tn Antigen Mimetics into the MUC1

open access: yes, 2023
Carmen Breton   +4 more
openaire   +2 more sources

Conjugate Vaccines Targeting Tumor-Associated Carbohydrate Antigens. [PDF]

open access: yesVaccines (Basel)
Rosenglick N   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy